Rituximab and new regimens for indolent lymphoma: a brief update from 2012 ASCO Annual Meeting

Zhao, Jiangning; Xu, Zhenshu; Liu, Delong; Lu, Quanyi

doi:10.1186/1475-2867-12-38

Cited by 8 publications

(8 citation statements)

References 56 publications

(33 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There is suggestive prior evidence for an association between rituximab‐containing regimens and risk of secondary AML (Zhao et al , ; Zhou et al , ; Lam et al , ), but studies investigating the risk of SPMs during time periods when monoclonal antibodies were used widely for treatment of haematological malignancies are sparse (Baldo, ). Significant excesses of AML have been reported among lymphoma patients, and our SIR of 4·39 for secondary AML in the pre‐rituximab era was very close to the SIRs reported in two SEER reports [4·83(Morton et al , ) and 4·96(Travis et al , )].…”

Section: Discussionmentioning

confidence: 99%

Subsequent primary malignancies after diffuse large B‐cell lymphoma in the modern treatment era

Clarke

Rosenberg

et al. 2017

Br J Haematol

View full text Add to dashboard Cite

Summary With the addition of rituximab and other treatment advances, survival after diffuse large B-cell lymphoma (DLBCL) has improved, but subsequent primary malignancies (SPMs) have emerged as an important challenge for DLBCL survivorship. We calculated standardized incidence ratios (SIRs) and 95% confidence intervals (CIs) for SPMs among 23,879 patients who survived at least 1 year after a first primary DLBCL diagnosed during 1989–2012, compared to the general population in California. Cumulative incidence (CMI) of SPMs, accounting for the competing risk of death, also was calculated. We found that the incidence of acute myeloid leukaemia (AML) nearly doubled in the post-rituximab era [SIR (95%CI) 4.39 (2.51–7.13) pre- (1989–2000) and 8.70 (6.62–11.22) post-rituximab (2001–2012)]. Subsequent thyroid cancer was rare pre-rituximab, but increased substantially after 2001 [0.66 (0.08–2.37) vs. 2.27(1.44–3.41)]. The 5-year CMI for all SPMs (4.77% pre- vs. 5.41% post-rituximab, P=0.047), AML (0.15% vs. 0.41%, P=0.003), thyroid cancer (0.03% vs. 0.15%, P=0.003) and melanoma (0.25% vs. 0.42%, P=0.020) were greater in DLBCL patients diagnosed in the post-versus pre-rituximab period. This study provides insight into the changing pattern of SPM occurrence after the introduction of rituximab, which may elucidate the aetiology of SPMs and should guide future cancer surveillance efforts among DLBCL patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Subsequent primary malignancies after diffuse large B‐cell lymphoma in the modern treatment era

Clarke

Rosenberg

et al. 2017

Br J Haematol

View full text Add to dashboard Cite

show abstract

“…Lenalidomide, an immunomodulator used in multiple myeloma treatment, may increase t-AML risk [60] . For rituximab-containing regimens (often used in non-Hodgkin lymphoma), there is also suggestive evidence for an association with acute myeloid leukaemia (AML) [61,62] , but generally studies investigating the risk of SMNs with the wider use of monoclonal antibodies are lacking [63] . Finally, in terms of SMN risks and hormonal treatments, tamoxifen has been associated with two- to five fold duration-dependent increased risk of endometrial cancer [64–66] .…”

Section: Systemic Treatmentsmentioning

confidence: 99%

Current knowledge and future research directions in treatment-related second primary malignancies

Morton

Swerdlow

Schaapveld

et al. 2014

European Journal of Cancer Supplements

View full text Add to dashboard Cite

Currently, 17–19% of all new primary malignancies occur in survivors of cancer, causing substantial morbidity and mortality. Research has shown that cancer treatments are important contributors to second malignant neoplasm (SMN) risk.In this paper we summarise current knowledge with regard to treatment-related SMNs and provide recommendations for future research. We address the risks associated with radiotherapy and systemic treatments, modifying factors of treatment-related risks (genetic susceptibility, lifestyle) and the potential benefits of screening and interventions. Research priorities were identified during a workshop at the 2014 Cancer Survivorship Summit organised by the European Organisation for Research and Treatment of Cancer.Recently, both systemic cancer treatments and radiotherapy approaches have evolved rapidly, with the carcinogenic potential of new treatments being unknown. Also, little knowledge is available about modifying factors of treatment-associated risk, such as genetic variants and lifestyle. Therefore, large prospective studies with biobanking, high quality treatment data (radiation dose–volume, cumulative drug doses), and data on other cancer risk factors are needed. International collaboration will be essential to have adequate statistical power for such investigations. While screening for SMNs is included in several follow-up guidelines for cancer survivors, its effectiveness in this special population has not been demonstrated. Research into the pathogenesis, tumour characteristics and survival of SMNs is essential, as well as the development of interventions to reduce SMN-related morbidity and mortality. Prediction models for SMN risk are needed to inform initial treatment decisions, balancing chances of cure and SMNs and to identify high-risk subgroups of survivors eligible for screening.

show abstract

“…Rituximab, the first monoclonal antibody against CD20 molecule, has revolutionized lymphoma therapy [1,2]. More monoclonal antibodies targeting different antigens are being developed for lymphoma therapy [3].…”

mentioning

confidence: 99%

CD19: a biomarker for B cell development, lymphoma diagnosis and therapy

2012

Self Cite

View full text Add to dashboard Cite

The human CD19 antigen is a 95 kd transmembrane glycoprotein belonging to the immunoglobulin superfamily. CD19 is classified as a type I transmembrane protein, with a single transmembrane domain, a cytoplasmic C-terminus, and extracellular N-terminus. CD19 is a biomarker for normal and neoplastic B cells, as well as follicular dendritic cells. CD19 is critically involved in establishing intrinsic B cell signaling thresholds through modulating both B cell receptor-dependent and independent signaling. CD19 functions as the dominant signaling component of a multimolecular complex on the surface of mature B cells, alongside complement receptor CD21, and the tetraspanin membrane protein CD81 (TAPA-1), as well as CD225. Through study of CD19 transgenic and knockout mouse models, it becomes clear that CD19 plays a critical role in maintaining the balance between humoral, antigen-induced response and tolerance induction. This review also summarized latest clinical development of CD19 antibodies, anti-B4-bR (an immunotoxin conjugate), blinatumomab (BiTE), and SAR3419 (huB4-DM4), a novel antibody-drug conjugate.

show abstract

Rituximab and new regimens for indolent lymphoma: a brief update from 2012 ASCO Annual Meeting

Cited by 8 publications

References 56 publications

Subsequent primary malignancies after diffuse large B‐cell lymphoma in the modern treatment era

Subsequent primary malignancies after diffuse large B‐cell lymphoma in the modern treatment era

Current knowledge and future research directions in treatment-related second primary malignancies

CD19: a biomarker for B cell development, lymphoma diagnosis and therapy

Contact Info

Product

Resources

About